IBBQ's concentrated biotech play has delivered a higher one-year return, while IXJ'S diversified global healthcare fund has been much less volatile.

Biotech remains one of the market's more out-of-favor sectors despite improving industry fundamentals. Here are three stocks trading near multiyear lows.

The biotech's diversification efforts continue.

In the latest close session, Recursion Pharmaceuticals (RXRX) was down 1.87% at $2.89. This change lagged the S&P 500's daily loss of 0.19%. At the same time, the Dow lost 0.59%, and the tech-heavy ...

PJP delivered stronger 5-year returns with lower volatility, while FBT offers broader biotech exposure at a slightly cheaper ...

The "Co-promotion and Co-marketing in Pharmaceuticals and Biotechnology 2016-2026" has been added to ResearchAndMarkets.com's offering.The Co-promotion and Co-marketing Deals in Pharmaceuticals and ...

While UK biotech financing recovery is present in the private markets, BIA CEO Chris Molloy notes that UK public sector backing is essential for sustained growth.

Innovative Pharmaceutical Biotech (HK:0399) has released an update. Innovative Pharmaceutical Biotech Limited has entered into a Memorandum of Understanding to potentially acquire a majority stake in ...

It's been a volatile year for the company, but don't let that scare you away.

Clinical-stage biopharmaceutical company Tonix Pharmaceuticals (NASDAQ: TNXP) is gaining significant attention from investors and market participants. The company develops therapies for conditions ...

DUBLIN--(BUSINESS WIRE)--The "Manufacturing and Supply Deals in Pharmaceuticals and Biotechnology 2020-2025" has been added to ResearchAndMarkets.com's offering. This report contains a comprehensive ...

Following the landmark success of CPHI & PMEC China in June 2026, which welcomed an unprecedented gathering of industry professionals and fostered pivotal connections across the pharmaceutical supply ...